Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ANG Lifesciences India's Revenue for the
three
months ended in Mar. 2026 was ₹235.0 Mil. ANG Lifesciences India's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₹679.3 Mil.
Hence, ANG Lifesciences India's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.35.
ANG Lifesciences India (BOM:540694) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ANG Lifesciences India Receivables Turnover Related Terms
ANG Lifesciences India Receivables Turnover Historical Data
* Premium members only.
The historical data trend for ANG Lifesciences India's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540694 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANG Lifesciences India Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ANG Lifesciences India's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANG Lifesciences India (BOM:540694) has a Receivables Turnover of 0.35 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ANG Lifesciences India and its competitors. According to the industry distribution chart, ANG Lifesciences India ranks #914 out of 946 companies in the Drug Manufacturers industry, placing it in the top 96.6%.
Is ANG Lifesciences India's Receivables Turnover too high?
ANG Lifesciences India's current Receivables Turnover is 0.35. The Drug Manufacturers industry median Receivables Turnover is 5.09. ANG Lifesciences India's value of 0.35 is 93.1% below this industry median. Based on the distribution chart, ANG Lifesciences India ranks #914 out of 946 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ANG Lifesciences India has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ANG Lifesciences India ranks #914 out of 946 companies for Receivables Turnover. This places ANG Lifesciences India in the lower half of its industry. The industry median Receivables Turnover is 5.09. ANG Lifesciences India's value of 0.35 is 93.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.09, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANG Lifesciences India's current Receivables Turnover of 0.35 is 93.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ANG Lifesciences India and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANG Lifesciences India's current Receivables Turnover is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹29.92, compared to a current price of ₹25.55 — trading 14.6% below its estimated fair value. The current Receivables Turnover is 0.35 and 93.1% below the Drug Manufacturers industry median of 5.09. ANG Lifesciences India's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current Receivables Turnover is 0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?
Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be undervalued.
The current stock price of ₹25.55 is trading 14.6% below its estimated GF Value™ of ₹29.92.
GuruFocus considers ANG Lifesciences India to be Modestly Undervalued.
Key valuation signals for BOM:540694:
Receivables Turnover: 0.35
GF Value™: ₹29.92 vs. price of ₹25.55 (14.6% below fair value)
Industry Position: 93.1% below the Drug Manufacturers median (#914 of 946)
No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
66GF Score
Get the complete analysis for BOM:540694
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540694 has been successfully added to your 
